Product image of Multihance (Gadobenate Dimeglumine) supplied by GNH India

Multihance

Active Ingredient:
Gadobenate Dimeglumine
Origin:
EU

Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as a 0.5 mmol/mL injection solution for intravenous use. It enhances magnetic resonance imaging of the central nervous system, liver, cardiovascular system and musculoskeletal system in patients undergoing diagnostic MRI examinations.

GNH India supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide with reliable, quality‑assured product deliveries. The company adheres to stringent regulatory standards and provides comprehensive technical support to ensure optimal use in diagnostic imaging procedures.

Manufacturer / TM Owner

Bracco Imaging S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Multihance is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging across several organ systems.
  • Central nervous system: provides enhanced delineation of brain and spinal cord structures for improved diagnostic confidence.
  • Liver: improves lesion detection and characterization during hepatic MRI examinations.
  • Cardiovascular system: enhances visualization of cardiac chambers, vessels and myocardial perfusion.
  • Musculoskeletal system: increases contrast between bone, cartilage and soft tissues for detailed joint assessment.

How It Works

  • Gadobenate dimeglumine is a paramagnetic gadolinium chelate that shortens T1 relaxation time of nearby water protons. When administered intravenously, it distributes into the extracellular fluid and accumulates in tissues with increased vascularity or disrupted blood‑brain barriers, thereby increasing signal intensity on T1‑weighted MRI sequences and improving image contrast.

Side Effects

Multihance may cause a range of adverse reactions following intravenous administration.

Common Side Effects

  • Nausea or vomiting
  • Headache or dizziness
  • Warmth or flushing sensation at the injection site
  • Mild injection‑site pain or discomfort
  • Transient metallic taste
  • Mild hypotension

Serious or Rare Side Effects

  • Nephrogenic systemic fibrosis in patients with severe renal impairment
  • Severe allergic reactions, including anaphylaxis
  • Acute respiratory distress or bronchospasm
  • Cardiac arrest or severe hypotension
  • Persistent skin rash or urticaria
  • Renal function deterioration

Precautions & Warnings

  • Before using Multihance, consider the following safety measures.
  • Renal function assessment: evaluate kidney function prior to administration.
  • Pregnancy: use only if clearly needed after risk‑benefit assessment.
  • Allergy history: screen for prior reactions to gadolinium‑based agents.
  • Concurrent medications: review use of other contrast agents or nephrotoxic drugs.
  • Patient monitoring: observe for immediate adverse reactions during and after injection.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Multihance may interact with other agents; monitor patients accordingly.

Major Interactions (Avoid)

  • Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid use.
  • Recent high‑dose iodinated contrast (within 24 h): may compound nephrotoxicity.
  • Chelating agents (e.g., deferoxamine): can displace gadolinium and increase toxicity.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: may affect renal clearance, requiring closer renal monitoring.
  • Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): monitor kidney function during combined use.

Frequently Asked Questions

Multihance is an intravenous gadolinium‑based contrast agent used to enhance magnetic resonance imaging of the central nervous system, liver, cardiovascular system and musculoskeletal structures. It improves the visibility of lesions, vessels and tissue differentiation, aiding radiologists in accurate diagnosis.

Gadobenate dimeglumine is a paramagnetic chelate that shortens the T1 relaxation time of nearby water protons. After intravenous injection, it distributes in the extracellular space and accumulates in areas with increased vascularity or disrupted barriers, producing higher signal intensity on T1‑weighted MRI scans.

The dose of Multihance is determined by the prescribing physician based on the patient’s weight, renal function and the specific MRI protocol. Dosing is individualized and administered as a single intravenous bolus prior to image acquisition.

The pregnancy category for Gadobenate dimeglumine is unknown. It should be used during pregnancy only if the potential diagnostic benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as limited data are available on excretion in milk.

To order Multihance, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Multihance (gadobenate dimeglumine) offers higher relaxivity than many conventional agents, providing stronger T1 enhancement at lower doses. Compared with alternatives such as gadobutrol (Gadavist) or gadoterate meglumine (Dotarem), Multihance may deliver improved lesion conspicuity, especially in liver imaging, while sharing a similar safety profile when used appropriately.

Multihance should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any product that appears discolored or contains particles.

Multihance is administered as a single intravenous injection, typically as a rapid bolus immediately before the MRI sequence. The injection is performed by qualified healthcare personnel using aseptic technique, and patients are monitored for any immediate reactions during and after administration.

The most serious risks include nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment and severe allergic reactions such as anaphylaxis. Prompt recognition and management of these reactions are essential, and the drug should be avoided in high‑risk individuals.

Multihance should not be used in patients with known hypersensitivity to gadobenate dimeglumine or any component of the formulation, and it is contraindicated in individuals with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of NSF. Caution is also advised for patients with a history of severe allergic reactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Gadobenate Dimeglumine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT